Introduction: The Growing Burden of Diabetic Vascular Complications

Diabetes mellitus now affects more than 530 million adults globally, a figure projected to exceed 780 million by 2045. Chronic hyperglycemia—the defining feature of diabetes—initiates a complex cascade of metabolic, inflammatory, and hemodynamic disturbances that progressively damage the endothelium, the single‑cell lining of blood vessels. This endothelial injury is the common root of both macrovascular complications (coronary artery disease, stroke, peripheral artery disease) and microvascular complications (retinopathy, nephropathy, neuropathy). Early detection of vascular damage is critical because these complications often remain asymptomatic until advanced, irreversible stages. Traditional diagnostic tools such as angiography, carotid intima‑media thickness, or albuminuria detect established disease, missing the window when intervention can still prevent or halt progression. Non‑invasive biomarkers that reflect ongoing endothelial injury offer a direct view into earlier phases of vascular pathology. Among them, circulating endothelial cell (CEC) biomarkers have emerged as one of the most promising tools for assessing diabetic vascular damage in real time.

The Endothelium in Diabetic Vascular Disease

Normal Endothelial Function and Homeostasis

The healthy endothelium is far more than a passive barrier. It actively regulates vascular tone, thrombosis, inflammation, and permeability. Endothelial cells release nitric oxide (NO) and prostacyclin to maintain vasodilation, prevent platelet aggregation, inhibit leukocyte adhesion, and suppress smooth muscle proliferation. The integrity of this monolayer is preserved through a delicate equilibrium between cell renewal (from adjacent endothelial cells and bone marrow‑derived progenitor cells) and cell turnover (apoptosis or detachment). When this balance is disrupted, the endothelium becomes dysfunctional, setting the stage for atherosclerosis and microvascular occlusion.

Hyperglycemia‑Induced Endothelial Injury: Key Mechanisms

Chronic exposure to elevated glucose levels damages endothelial cells through several interconnected pathways:

  • Increased oxidative stress: Hyperglycemia drives overproduction of mitochondrial reactive oxygen species (ROS). ROS inactivate NO, promote lipid peroxidation, and activate pro‑inflammatory transcription factors such as NF‑κB.
  • Formation of advanced glycation end‑products (AGEs): Non‑enzymatic glycation of proteins, lipids, and nucleic acids yields AGEs, which bind to receptors (RAGE) on endothelial cells, triggering oxidative stress, inflammation, and apoptosis.
  • Activation of the polyol pathway: Excess glucose is converted to sorbitol, depleting NADPH and glutathione, thereby reducing antioxidant capacity.
  • Protein kinase C (PKC) activation: Hyperglycemia increases diacylglycerol, which activates PKC isoforms. PKC impairs NO production, increases endothelial permeability, and promotes expression of pro‑coagulant and pro‑inflammatory molecules.

These insults collectively disrupt NO signaling, promote a pro‑thrombotic and pro‑inflammatory state, and accelerate endothelial cell apoptosis and detachment. The result is a dysfunctional, leaky endothelium prone to atherosclerosis, thrombosis, and microvascular occlusion.

Measuring Endothelial Damage: The Circulating Endothelial Cell Concept

When endothelial cells are injured, they detach from the basement membrane and enter the bloodstream. These detached cells are referred to as circulating endothelial cells (CECs). In healthy individuals, CEC counts are extremely low—typically fewer than 20 cells per milliliter of blood, with most studies reporting <10 cells/mL. Elevated CEC counts are observed in conditions marked by significant endothelial injury, including diabetes, hypertension, acute coronary syndromes, vasculitis, and sepsis. In diabetes, CEC levels correlate with disease duration, glycemic control (HbA1c), and the presence and severity of complications. Because CECs originate directly from the vessel wall, they provide a direct, real‑time snapshot of ongoing endothelial injury, making them a unique and valuable biomarker.

Circulating Endothelial Cells as Biomarkers of Diabetic Vascular Damage

Origin, Identification, and Phenotyping

CECs are mature, terminally differentiated endothelial cells that have shed from the intimal lining. They can be identified by their expression of endothelial‑specific markers such as CD146 (Mel‑CAM), CD31 (PECAM‑1), von Willebrand factor (vWF), and CD105 (endoglin), combined with absence of the hematopoietic marker CD45. Using flow cytometry or immunomagnetic separation, investigators count CECs and characterize their viability status—distinguishing viable, apoptotic, and necrotic subtypes. This phenotyping may provide additional information: for instance, a predominance of apoptotic CECs suggests ongoing injury with preserved apoptotic machinery, while necrotic CECs indicate more severe, lytic damage. The size, granularity, and surface marker density of CECs can also vary depending on the vascular bed of origin and the type of insult.

Clinical Evidence: Elevated CECs in Diabetes

A growing body of evidence demonstrates that patients with both type 1 and type 2 diabetes have significantly higher CEC counts compared to age‑matched controls. A landmark study by McClung et al. (2008) found that CEC levels were three‑ to four‑fold higher in diabetic patients and correlated positively with HbA1c and with microalbuminuria, an early marker of nephropathy. Subsequent studies confirmed that CEC numbers increase with the duration of diabetes and worsen with the development of complications. In diabetic retinopathy, CEC counts rise progressively from non‑proliferative to proliferative stages, reflecting breakdown of the blood‑retinal barrier. In nephropathy, CEC levels correlate with albumin excretion rate and declining eGFR. In neuropathy, higher CEC counts are associated with reduced nerve conduction velocities and symptomatic peripheral neuropathy. Notably, CEC levels also predict future cardiovascular events in diabetic populations, independent of traditional Framingham risk factors, suggesting that CEC measurement could enhance risk stratification.

CECs and Macrovascular Complications

In patients with diabetes and established coronary artery disease, CEC counts are further elevated compared to diabetic patients without coronary disease. CEC numbers correlate with the extent of coronary atherosclerosis assessed by coronary angiography or CT calcium scoring. More importantly, the phenotype of CECs may reflect plaque instability: patients with acute coronary syndrome have a higher proportion of apoptotic or necrotic CECs compared to those with stable angina. This suggests that CECs not only indicate the burden of endothelial damage but may also detect active plaque erosion or rupture, providing a window into the pathophysiology of acute vascular events. Similarly, in peripheral artery disease, CEC levels are elevated in patients with critical limb ischemia and drop after successful revascularization.

CECs and Microvascular Complications

Microvascular disease is a hallmark of diabetes, and CECs have been studied across all major target organs:

  • Retinopathy: CEC numbers increase with retinopathy stage, from mild non‑proliferative to proliferative diabetic retinopathy. They are associated with vitreous levels of vascular endothelial growth factor (VEGF) and with breakdown of the blood‑retinal barrier.
  • Nephropathy: Elevated CEC counts correlate with urinary albumin‑to‑creatinine ratio and with histologic evidence of glomerular endothelial injury. They also predict progression of albuminuria and decline in renal function.
  • Neuropathy: Endothelial dysfunction of the vasa nervorum contributes to nerve ischemia. Studies show higher CEC counts in patients with symptomatic diabetic neuropathy compared to those without, and CEC levels correlate with neuropathy severity scores.

These associations support CECs as a unifying marker of microvascular damage across different organ systems, potentially enabling a single blood test to assess total microvascular burden.

Other Endothelial‑Derived Biomarkers: Microparticles and Progenitor Cells

Endothelial Microparticles (EMPs)

Endothelial microparticles are small (0.1–1 μm) membrane vesicles released from endothelial cells undergoing activation, injury, or apoptosis. They carry surface proteins (e.g., CD144, CD146, CD31), cytoplasmic components, and microRNAs that reflect the state of the parent cell. In diabetes, EMP levels are elevated and correlate with HbA1c, oxidative stress markers, and the presence of vascular complications. EMPs are pro‑coagulant (exposing phosphatidylserine and tissue factor) and pro‑inflammatory, actively contributing to the ongoing vascular pathology. Compared to CECs, EMPs are more abundant in circulation and may capture information about endothelial activation in addition to injury. However, their small size makes detection and standardization more challenging, and different isolation methods yield varying results.

Circulating Endothelial Progenitor Cells (EPCs)

Endothelial progenitor cells are bone marrow‑derived cells that migrate to sites of vascular injury and contribute to endothelial repair. They express characteristic markers such as CD34, KDR (VEGFR‑2), and CD133. In diabetes, both the number and the functional capacity of EPCs are reduced, reflecting impaired vascular repair. The balance between injury (CECs, EMPs) and repair (EPCs) is thought to determine net vascular health. The CEC/EPC ratio, in particular, has been proposed as a more comprehensive biomarker: a high ratio indicates ongoing injury with insufficient repair, a scenario strongly associated with progression of diabetic complications. Combining CECs, EMPs, and EPCs in a multimodal assessment may provide a more complete picture of endothelial health than any single marker alone.

Clinical Significance and Practical Applications

Risk Stratification

Measuring CECs and related biomarkers can identify diabetic patients at the highest risk for vascular events, even when traditional risk factors appear well‑controlled. For example, a patient with an HbA1c of 7.5% but markedly elevated CECs may deserve more aggressive glucose management, earlier initiation of antiplatelet therapy, or earlier screening for retinopathy and nephropathy. CEC levels might also help decide when to start statin or ACE‑inhibitor therapy beyond current risk score‑based thresholds. In intermediate‑risk populations, adding CEC measurement to the ASCVD risk calculator could improve discrimination and reclassification.

Monitoring Treatment Response

Endothelial damage is potentially reversible with improved glycemic control, lifestyle changes, and pharmacologic interventions. Several studies have shown that CEC and EMP levels decrease after treatment with insulin, metformin, or newer agents such as SGLT2 inhibitors and GLP‑1 receptor agonists. For instance, a 2022 study found that six months of dapagliflozin therapy reduced CEC counts by 40% in patients with type 2 diabetes and heart failure. Similarly, interventions such as supervised exercise training, dietary modification, and smoking cessation reduce endothelial injury markers. Serial monitoring of CECs could provide an objective, real‑time measure of treatment efficacy and help motivate patient adherence. In clinical trials, endothelial biomarkers can serve as surrogate endpoints for vascular outcomes, potentially shortening study durations and reducing sample size requirements.

Predicting Cardiovascular Events

Prospective data support the ability of CECs to predict future cardiovascular events in both diabetic and non‑diabetic populations. A meta‑analysis of 10 studies involving over 2,500 patients found that elevated CECs were associated with a 2.5‑fold increased risk of major adverse cardiovascular events (MACE). Importantly, this association remained significant after adjustment for traditional risk factors, including age, sex, smoking, hypertension, and low‑density lipoprotein cholesterol. Adding CEC measurement to existing risk prediction models (e.g., the UKPDS risk engine for diabetes) may improve discrimination and reclassification, especially in patients classified as intermediate risk. This could lead to earlier and more targeted use of preventive therapies.

Measurement Techniques and Challenges

Flow Cytometry

The most common method for quantifying CECs is flow cytometry, using fluorescently labeled antibodies against endothelial markers such as CD146, CD31, and CD105, while excluding CD45‑positive leukocytes. However, distinguishing true CECs from platelets (which express CD31), platelet‑leukocyte aggregates, and cellular debris requires careful gating and the use of viability dyes (e.g., 7‑AAD, propidium iodide). Inter‑laboratory variability remains a major hurdle to clinical adoption. Factors such as time from blood draw to processing, type of anticoagulant (EDTA vs. citrate), storage temperature, and centrifugation speed all affect CEC counts. Consensus guidelines from the International Society on Thrombosis and Haemostasis (ISTH) have standardized some aspects, but differences in antibody panels, gating strategies, and enumeration protocols persist. Harmonization efforts, such as the Endothelial Cell Counting Standardization Initiative, are ongoing.

Immunomagnetic Separation

This technique uses magnetic beads coated with anti‑CD146 or anti‑CD34 antibodies to capture CECs from whole blood. The captured cells are then stained with endothelial‑specific fluorescent antibodies and counted manually or by automated microscopy. Immunomagnetic separation yields high purity and allows for detailed morphologic assessment, but it is labor‑intensive, requires dedicated equipment, and is less suited for high‑throughput clinical laboratories. Newer automated platforms, such as the RareCyte system or the CellSearch system (already FDA‑cleared for circulating tumor cells), aim to streamline isolation and analysis, but their performance for CECs in diabetes has not been extensively validated.

Molecular and Omics Approaches

Emerging techniques focus on measuring CEC‑specific RNA transcripts, microRNAs, or DNA methylation patterns released into the circulation. For example, endothelial‑specific microRNAs such as miR‑126, miR‑92a, and miR‑222 are enriched in CECs and EMPs and may provide information about the functional state of the detached cells. Proteomic profiling of CECs and EMPs could identify novel markers of vascular damage and repair. While these approaches are still in the research phase, they have the potential to increase sensitivity and specificity, and to provide mechanistic insights beyond cell counting.

Standardization and Reference Ranges

A critical barrier to clinical use is the lack of widely accepted reference ranges. CEC counts vary with age (higher in older adults), sex, recent exercise (transient increase), and even circadian rhythm. In healthy individuals, most laboratories report a normal range of 0–10 cells/mL, but some cite up to 20 cells/mL. Without consensus cut‑offs, interpreting individual results is difficult. Multi‑center collaborative efforts, such as those coordinated by the Vascular Medicine Institute and the European Vascular Biology Network, are working to establish normative data across diverse populations, define clinically meaningful thresholds, and validate decision limits that predict outcomes.

Future Directions

Integration with Other Biomarkers and Machine Learning

The full potential of CEC biomarkers may be realized when combined with other endothelial measures (EMPs, EPCs, sICAM‑1, sVCAM‑1, sE‑selectin) and clinical variables. Multivariable models that incorporate CEC counts, HbA1c, blood pressure, lipid profile, and biomarkers of inflammation (hs‑CRP) could outperform current risk calculators. Machine learning algorithms can help identify complex, non‑linear patterns of biomarker changes that precede clinical events, potentially enabling prediction weeks or months before symptom onset. Such models could be integrated into electronic health records to provide real‑time decision support.

Point‑of‑Care Devices

Miniaturized flow cytometers, microfluidic chips, and image‑based cell counting devices that can count and characterize CECs at the bedside are in active development. For example, a handheld device using acoustic focusing of cells and laser‑induced fluorescence detection could report CEC counts within minutes from a single drop of blood. If validated, such technology could be deployed in primary care offices, endocrinology clinics, or even home‑monitoring settings to guide diabetes management and empower patients.

Cell‑Free DNA of Endothelial Origin

Another emerging area is the measurement of cell‑free DNA (cfDNA) derived from endothelial cells. During apoptosis or necrosis, endothelial cells release DNA fragments into the circulation. Methylation‑specific polymerase chain reaction can quantify fragments with endothelial‑specific methylation patterns (e.g., in the CDH5 gene promoter). This approach does not require intact cells, avoids many pre‑analytical concerns, and can be performed on stored plasma samples, facilitating large‑scale retrospective studies. Early data suggest that endothelial cfDNA levels correlate with CEC counts and predict vascular outcomes in diabetes.

Personalized Vascular Care

Ultimately, endothelial biomarkers could become a cornerstone of personalized medicine for diabetes. A patient’s “vascular phenotype”—reflected by the relative abundance of CECs, EMPs, and EPCs—could guide selection of the most appropriate glucose‑lowering agent, anti‑hypertensive, or anti‑platelet regimen. For instance, an individual with high CEC levels and low EPC counts might benefit preferentially from an SGLT2 inhibitor, which has been shown to increase EPC numbers and reduce CECs in some studies. Real‑time biomarker feedback could also help patients understand the link between daily behaviors (diet, exercise, sleep) and their vascular health, reinforcing lifestyle modifications.

Conclusion

Circulating endothelial cell biomarkers offer a direct, non‑invasive window into the vascular damage that underlies the most feared complications of diabetes. Elevated CEC counts signal ongoing endothelial injury, while combined assessment with endothelial microparticles and progenitor cells provides a more complete picture of the injury‑repair balance. Despite persistent challenges in standardization, measurement, and reference range establishment, the clinical promise of these markers is substantial. They can improve risk stratification beyond traditional factors, monitor therapeutic response in real time, and predict future cardiovascular events. As measurement techniques mature and large‑scale validation studies are completed, integrating CEC‑based assays into routine diabetes care may become a reality. Clinicians who understand these biomarkers will be better equipped to identify at‑risk patients earlier and tailor interventions to preserve vascular health, ultimately reducing the heavy burden of diabetic vascular disease.

Selected References

  • McClung JA, Naseer N, Saleem M, et al. Circulating endothelial cells are elevated in patients with type 2 diabetes mellitus independently of HbA1c. Diabetologia 2008;51(8):1441‑1448. DOI
  • Dignat‑George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011;31(1):27‑33. DOI
  • Fadini GP, Avogaro A. The regenerative potential of endothelial progenitor cells in diabetes. Diabetologia 2022;65(12):1999‑2011. DOI
  • Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003;42(7):1149‑1160. DOI
  • American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl 1). DOI